BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su Y, Liu X, Lian J, Deng C. Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders. Pharmacological Research 2020;155:104703. [DOI: 10.1016/j.phrs.2020.104703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen S, Lian J, Su Y, Deng C. Effects of Risperidone and Prenatal Poly I:C Exposure on GABAA Receptors and AKT-GSK3β Pathway in the Ventral Tegmental Area of Female Juvenile Rats. Biomolecules 2022;12:732. [PMID: 35625659 DOI: 10.3390/biom12050732] [Reference Citation Analysis]
2 Sun B, Long Y, Xiao L, Wang J, Yi Q, Tong D, Li K, Wu G. Target Protein for Xklp2 Functions as Coactivator of Androgen Receptor and Promotes the Proliferation of Prostate Carcinoma Cells. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/6085948] [Reference Citation Analysis]
3 Han M, Lian J, Su Y, Deng C. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats. J Psychopharmacol 2021;:2698811211050549. [PMID: 34694173 DOI: 10.1177/02698811211050549] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Hime GR, Stonehouse SL, Pang TY. Alternative models for transgenerational epigenetic inheritance: Molecular psychiatry beyond mice and man. World J Psychiatr 2021; 11(10): 711-735 [PMID: 34733638 DOI: 10.5498/wjp.v11.i10.711] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen CH, Leu SJ, Hsu CP, Pan CC, Shyue SK, Lee TS. Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway. Metabolism 2021;123:154847. [PMID: 34364926 DOI: 10.1016/j.metabol.2021.154847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Li R, Zhu W, Huang P, Yang Y, Luo F, Dai W, Shen L, Pei W, Huang X. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomed Pharmacother 2021;141:111803. [PMID: 34146854 DOI: 10.1016/j.biopha.2021.111803] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
7 Zhou YQ, Mei W, Tian XB, Tian YK, Liu DQ, Ye DW. The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies. Pharmacol Ther 2021;225:107846. [PMID: 33819559 DOI: 10.1016/j.pharmthera.2021.107846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liu X, Feng X, Deng C, Liu L, Zeng Y, Hu CH. Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin. BMC Pharmacol Toxicol 2020;21:48. [PMID: 32605639 DOI: 10.1186/s40360-020-00427-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li C, Chen Y, Yuan X, He L, Li X, Huang S, Hou S, Liang J. Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation. Eur J Pharmacol 2020;882:173264. [PMID: 32544504 DOI: 10.1016/j.ejphar.2020.173264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]